Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review - 01/03/18
Résumé |
Background |
Proton pump inhibitors (PPIs) are a commonly prescribed medication that recent data has linked to an increased risk of cardiovascular morbidity and all cause morbidity. The current study sought to perform a systematic review to investigate the link between PPIs and morbidity and mortality
Methods |
A systematic review was carried out as per the PRISMA guidelines, with information databases including Pubmed, Medline, and the Cochrane Review Database. English-language studies of all types published from January 1990 to October 2016 were considered. Dichotomous analysis generating odds ratios was performed using RevMan Version 5.3.
Results |
Thirty-seven studies were considered, of which five directly compared the effect of PPI use on mortality and/or cardiovascular morbidity (including 22,427 patients in mortality datasets, and 354,446 patients in morbidity datasets). For patients taking PPIs, all cause mortality (OR 1.68 [95% CI 1.53–1.84], p<0.001) and rate of major cardiovascular events (OR 1.54 [95% CI 1.11–2.13], p=0.01) were significantly higher.
Conclusions |
The current systematic review demonstrates that, in patients using PPIs, there was a significant increase in morbidity due to cardiovascular disease. Careful consideration should be given to the prescription of PPIs while clinical equipoise remains. Further research in the area is required.
Le texte complet de cet article est disponible en PDF.Keywords : Proton pump inhibitor, Myocardial infarct, Cardiovascular disease, ADMA, Nitric oxide, Mortality
Plan
Vol 27 - N° 4
P. 443-450 - avril 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?